HighPoint Advisor Group LLC Acquires Shares of 3,596 Insmed Incorporated (NASDAQ:INSM)

HighPoint Advisor Group LLC acquired a new position in Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,596 shares of the biopharmaceutical company's stock, valued at approximately $248,000.

Other large investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC grew its holdings in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC boosted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed in the 4th quarter worth about $47,000. Smartleaf Asset Management LLC increased its stake in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed during the 4th quarter valued at about $86,000.

Insmed Stock Performance

NASDAQ:INSM traded down $1.08 on Tuesday, hitting $67.01. The stock had a trading volume of 442,117 shares, compared to its average volume of 2,235,408. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock has a market cap of $12.13 billion, a price-to-earnings ratio of -11.98 and a beta of 1.07. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The business's 50-day simple moving average is $77.59 and its two-hundred day simple moving average is $73.93.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 6,172 shares of the company's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the transaction, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. This represents a 5.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now owns 97,083 shares in the company, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 514,731 shares of company stock worth $40,530,912 in the last three months. Corporate insiders own 4.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on INSM shares. Guggenheim restated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Bank of America increased their target price on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus cut their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.